The global allergy diagnostics and therapeutics market size was valued at USD 32.06 billion in 2018 and is anticipated to expand further at a strong CAGR of 6.3% over the forecast period. Increasing incidences of allergic diseases coupled with high demand for in vitro diagnostic blood tests are projected to drive the industry growth in the coming years.
According to the estimates published by the World Health Organization (WHO), around 40 million cases of inhaled allergies were reported in 2012 in the U.S. and the number is increasing contributing toward the growth of this market. Also, factors, such as changing lifestyles, increasing levels of indoor and outdoor pollution, poor dietary habits, and rapid urbanization across the globe are estimated to result in increased incidences of allergic conditions.
This, in turn, is projected to help augment the market growth over the next few years. The introduction of technologically advanced diagnostic and therapeutic products, which offer highly sensitive and accurate results, is also expected to have a positive impact on the market growth of the global market over the forecast period.
The inhaled allergen type segment accounted for the largest market share in 2018 and is projected to maintain its dominance over the forecast years. This growth can be attributed to the increasing cases of respiratory allergies. According to the statistics published in 2012 by the American Academy of Allergy Asthma and Immunology (AAAAI), around 7.8 million children suffered from respiratory allergies worldwide.
In vivo test was the largest test segment in 2018 and accounted for half of the overall share owing to associated benefits, such as ease of use, time efficiency, wider availability, and sensitivity for clinically valid allergies. Skin prick tests accounted for the largest revenue share in 2018 owing to greater adoption by healthcare professionals and patients. The segment is projected to expand further at the highest CAGR of 11.0% from 2019 to 2025.
This is mainly due to the rising applicability of skin prick tests in food allergy detection, specific IgE mediated allergy testing. In vitro test segment is also expected to witness significant growth in the coming years owing to increasing demand for less invasive diagnostic methods, lab automation, and highly sensitive and accurate results. Companies in the market are also focusing on providing allergy-specific solutions, accurate result-oriented devices to gain the maximum market share.
The product segment includes instruments, consumables, and services. Consumables led the overall market in 2018 as they are an indispensable component in allergy detection. Technological advancements, such as allergen microarray kits, which are more sensitive and offer individualized patient profiling and monitoring, are projected to drive the segment further. Besides, the advent of products, such as MeDALL allergen-chip associated with enhanced sensitivity specificity, and faster diagnosis is projected to support the market expansion.
Based on allergen type, the market is categorized into food, inhaled, drug, and others. Inhaled allergen led the global allergy diagnostics and therapeutics market in 2018 due to increased incidences of respiratory allergies and asthma across the globe. The segment is projected to expand further at the fastest CAGR owing to the high demand for allergy testing and the introduction of specific allergen for the detection of allergy.
The drug allergies segment is also expected to register a strong CAGR of 11.3% from 2019 to2025. Food allergies were the second-largest segment, in terms of revenue share, and is projected to continue the trend throughout the forecast years. Children are more susceptible to these types of allergic diseases. According to the estimates published by the U.S. National Institute of Health (NIH), the prevalence of food allergies among children is double that of adults.
Antihistamines accounted for the largest market share in 2018 on account of their associated benefits and wide applications in the treatment of allergy diseases. According to the estimates published by the American Academy of Allergy Asthma & Immunology (AAAAI), allergic rhinitis affects approximately 10.0 to 30.0% of the global population, thereby contributing toward the adoption of allergy therapeutics. Major causes of allergic conditions include factors, such as changing lifestyle, poor dietary habits, and rising pollution levels.
The introduction of therapeutically advanced drugs, such as monoclonal antibodies possessing higher efficacy than conventional drugs, is expected to boost the market over the forecast period. Immunotherapy is expected to be the fastest-growing segment with a CAGR of 7.1% from 2019 to 2025 owing to increasing demand for sublingual vaccines, extensive drug pipeline, ongoing clinical trials of monoclonal antibodies for the treatment of allergic disorders, and growing awareness among patients.
Based on end-use, the market has been divide into academic research institutes, hospitals, and diagnostic laboratories. Diagnostic laboratories held the largest market share of 49.8% in 2018 due to extensive utilization of immunoassay tests in allergy diagnosis.
The advancements in screening techniques enabling accurate disease diagnosis and stratification for appropriate treatment is expected to drive the segment further. Hospitals are expected to be the fastest-growing segment due to supportive government funding and rising healthcare expenditure.
North America led the global market, in terms of revenue, in 2018 on account of a high incidence of respiratory allergic disorders along with rising awareness levels about allergy diagnostics and the adoption of in vitro blood tests. Europe is expected to be the second-largest regional market due to the presence of developed pharmaceutical industry and increasing demand for therapeutics. The growing geriatric population and rising incidences of allergic conditions are also contributing to the region’s growth. Asia Pacific is expected to be the fastest-growing regional market registering a CAGR of 13.2% from 2019 to 2025 due to rapidly improvising healthcare infrastructure, unmet clinical needs, and demand for minimally invasive diagnostic tools.
Some of the key companies in the global market include bioMerieux, Thermo Fisher Scientific, Danaher Corporation, Omega Diagnostics, Hitachi Chemical Diagnostics, Stallergenes Greer, Siemens Healthcare, Lincoln Diagnostics, Hycor Biomedical, HOB Biotech Group, and Alcon Laboratories. The market is highly competitive and companies are actively involved in new product launches, strategic collaborations, acquisitions, and technological advancements to gain maximum market share.
For example, in October 2017, Stallergenes Greer acquired Medic Savoure Ltd., thereby strengthening its presence in the Canadian allergy immunotherapy market. Also, in July 2016, Novartis AG received FDA approval for use of its product, Xolair, in the treatment of pediatric allergic asthma, which helped expand its product portfolio.
The base year for estimation
Actual estimates/Historical data
2014 - 2017
2019 - 2026
Revenue in USD Million and CAGR from 2019 to 2026
North America, Europe, Asia Pacific, Latin America, and Middle East & Africa
U.S., Canada, U.K., Germany, Japan, China, Brazil, and South Africa
Revenue forecast, company share, competitive landscape, growth factors, and trends
15% free customization scope (equivalent to 5 analysts working days)
If you need specific information, which is not currently within the scope of the report, we will provide it to you as a part of customization
This report forecasts revenue and volume growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2014 to 2026. For this study, Grand View Research has segmented the global allergy diagnostics and therapeutics market report based on the product, allergen type, end-use, diagnostic test, drug class, and region:
Product Outlook (Revenue, USD Million, 2014 - 2026)
Allergen Type Outlook (Revenue, USD Million, 2014 - 2026)
End-Use Outlook (Revenue, USD Million, 2014 - 2026)
Academic Research Institutes
Test Outlook (Revenue, USD Million, 2014 - 2026)
In vivo Test
Skin Prick Test
In vitro Test
Drug Class Outlook (Revenue, USD Million, 2014 - 2026)
Mast Cell Stabilizers
Regional Outlook (Revenue, USD Million, 2014 - 2026)
NEED A CUSTOM REPORT?
We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports, as well as offer affordable discounts for start-ups & universities.
Contact us now to get our best pricing.
We are GDPR and CCPA compliant! Your transaction & personal information is safe and secure.
"The quality of research they have done for us has been excellent..."
Multiple therapeutic regimens are being followed across the globe in attempts to come up with a reliable treatment for Covid-19. One line of treatment includes the use of hydroxychloroquine, while a second treatment line focuses to use antiviral drugs used in the disease management of HIV. Both these approaches have surged demand from advanced antivirals and antimalarial drugs. This impacts the drug manufacturers as an off label indication for these drug classes has to be worked upon. At the moment, the WHO has not prescribed any of these approaches, neither they have commented if one is better than the other. The report will account for Covid19 as a key market contributor.